Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice
Open Access
- 1 April 2000
- journal article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 164 (7) , 3535-3542
- https://doi.org/10.4049/jimmunol.164.7.3535
Abstract
CD4+ T cells play a central role in the induction and persistence of CD8+ T cells in several models of autoimmune and infectious disease. To improve the efficacy of a synthetic peptide vaccine based on the self-Ag, gp100, we sought to provide Ag-specific T cell help. To identify a gp100 epitope restricted by the MHC class II allele with the highest prevalence in patients with malignant melanoma (HLA-DRB1*0401), we immunized mice transgenic for a chimeric human-mouse class II molecule (DR4-IE) with recombinant human gp100 protein. We then searched for the induction of CD4+ T cell reactivity using candidate epitopes predicted to bind to DRB1*0401 by a computer-assisted algorithm. Of the 21 peptides forecasted to bind most avidly, murine CD4+ T cells recognized the epitope (human gp10044–59, WNRQLYPEWTEAQRLD) that was predicted to bind best. Interestingly, the mouse helper T cells also recognized human melanoma cells expressing DRB1*0401. To evaluate whether human CD4+ T cells could be generated from the peripheral blood of patients with melanoma, we used the synthetic peptide h-gp10044–59 to sensitize lymphocytes ex vivo. Resultant human CD4+ T cells specifically recognized melanoma, as measured by tumor cytolysis and the specific release of cytokines and chemokines. HLA class II transgenic mice may be useful in the identification of helper epitopes derived from Ags of potentially great clinical utility.Keywords
This publication has 64 references indexed in Scilit:
- Identification of LFA-1 as a Candidate Autoantigen in Treatment-Resistant Lyme ArthritisScience, 1998
- Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative TumorsThe Journal of Experimental Medicine, 1998
- Speed congenics: a classic technique in the fast lane (relatively speaking)Immunology Today, 1997
- DiscussionImmunology Today, 1997
- Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.The Journal of Experimental Medicine, 1996
- HLA Associations in the Antitumor Response Against Malignant MelanomaJournal of Immunotherapy, 1995
- Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning.The Journal of Experimental Medicine, 1994
- Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cellsInternational Journal of Cancer, 1994
- Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in sizeNature, 1992
- Sequence analysis of peptides bound to MHC class II moleculesNature, 1991